FDA Relaxes Demands on Gene Therapy, Peptide Markets

Key facts

• The FDA is rescinding some demands for regulated products.
• This includes a gene therapy for Huntington's disease.
• The booming peptide market is also affected by the FDA's decision.

The U.S. Food and Drug Administration is rolling back some of its requirements for certain regulated products. This decision specifically impacts a gene therapy developed for Huntington's disease, as well as the rapidly expanding market for peptides. The agency's action comes as these products are experiencing increased demand and significant development.